Clinical development of panobinostat in classical Hodgkin's lymphoma

Expert Review of Hematology

Volumn 4, Issue 3, 2011, Pages 245-252

  Oki, Yasuhiro ^a   Copeland, Amanda ^a   Younes, Anas ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

classical Hodgkin's lymphoma; epigenetic therapy; histone deacetylase inhibitor; panobinostat

Indexed keywords

BELINOSTAT; CARBOPLATIN; ENTINOSTAT; ETOPOSIDE; EVEROLIMUS; IFOSFAMIDE; MOCETINOSTAT; PANOBINOSTAT; VORINOSTAT;

ANEMIA; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; ASTHENIA; CANCER REGRESSION; CELL CYCLE ARREST; CONSTIPATION; DECREASED APPETITE; DIARRHEA; DRUG MECHANISM; DYSGEUSIA; ENZYME INHIBITION; FATIGUE; HODGKIN DISEASE; HUMAN; HYPOTHYROIDISM; LEUKOPENIA; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; THROMBOCYTOPENIA; VOMITING;

BENZAMIDES; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HODGKIN DISEASE; HUMANS; HYDROXAMIC ACIDS; PYRIDINES; PYRIMIDINES;

EID: 79959218179     PISSN: 17474086     EISSN: 17474094     Source Type: Journal    
DOI: 10.1586/ehm.11.24     Document Type: Article

References (38)

1. Taby R, Issa JP. Cancer epigenetics. CA Cancer J. Clin. 60(6), 376-392 (2010)
2. Esteller M. Epigenetics in cancer. N. Engl. J. Med. 358(11), 1148-1159 (2008)
3. Bhalla KN. Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies. J. Clin. Oncol. 23(17), 3971-3993 (2005)
4. Issa JP. DNA methylation as a therapeutic target in cancer. Clin. Cancer Res. 13(6), 1634-1637 (2007)
5. Kuendgen A, Lubbert M. Current status of epigenetic treatment in myelodysplastic syndromes. Ann. Hematol. 87(8), 601-611 (2008)
6. Singh BN, Zhang G, Hwa YL, Li J, Dowdy SC, Jiang SW. Nonhistone protein acetylation as cancer therapy targets. Expert Rev. Anticancer Ther. 10(6), 935-954 (2010)
7. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discov. 5(9), 769-784 (2006)
8. Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat. Rev. Cancer 6(1), 38-51 (2006)
9. Stimson L, Wood V, Khan O, Fotheringham S, La Thangue NB. HDAC inhibitor-based therapies and haematological malignancy. Ann. Oncol. 20(8), 1293-1302 (2009)
10. Gloghini A, Buglio D, Khaskhely NM et al. Expression of histone deacetylases in lymphoma: implication for the development of selective inhibitors. Br. J. Haematol. 147(4), 515-525 (2009)
11. Buglio D, Khaskhely NM, Voo KS, Martinez-Valdez H, Liu YJ, Younes A. HDAC11 plays an essential role in regulating OX40 ligand expression in Hodgkin lymphoma. Blood 117(10), 2910-2917 (2011)
12. Banerjee D. Recent advances in the pathobiology of Hodgkin s lymphoma: potential impact on diagnostic, predictive, and therapeutic strategies. Adv. Hematol. 2011, 439456 (2011)
13. Younes A, Bartlett NL, Leonard JP et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N. Engl. J. Med. 363(19), 1812-1821 (2010)
14. Johnston PB, Ansell SM, Colgan JP et al. mTOR inhibition for relapsed or refractory hodgkin lymphoma: promising single agent activity with everolimus (RAD001)Blood 110(11) (2007) (Abstract 2555)
15. Boll B, Borchmann P, Topp MS et al. Lenalidomide in patients with refractory or multiple relapsed Hodgkin lymphoma. Br. J. Haematol. 148(3), 480-482 (2010)
16. Sureda A, Younes A, Ben-Yehuda D et al. Final ANALYSIS: Phase II study of oral panobinostat in relapsed/refractory Hodgkin lymphoma patients following autologous hematopoietic stem-cell transplant. Blood 116(21) (2010) (Abstract 419)
17. Younes A, Bociek RG, Kuruvilla J et al. Mocetinostat (MGCD0103), an isotype-selective histone deacetylase (HDAC) inhibitor, produces clinical responses in relapsed/refractory hodgkin lymphoma (HL): update from a Phase II clinical study. Blood 116(21) (2010) (Abstract 1763)
18. Younes A, Hernandez F, Bociek RG et al. ENGAGE- 501: Phase 2 Study investigating the role of epigenetic therapy with entinostat (SNDX-275) In relapsed and refractory Hodgkin s lymphoma (HL), interim results. Blood 116(21) (2010) (Abstract 3959)
19. Kirschbaum MH, Goldman BH, Zain JM et al. Vorinostat (suberoylanilide hydroxamic acid) in relapsed or refractory Hodgkin lymphoma: SWOG 0517. Blood 110(11) (2007) (Abstract 2574)
20. Lemoine M, Buglio D, Jona A et al. The pan-deacetylase inhibitor panobinostat downregulates HIF-1 aand VEGF and, synergizes with everolimus in Hodgkin lymphoma cell lines. Blood 116(21) (2010) (Abstract 2851)
21. Younes A. Novel treatment strategies for patients with relapsed classical Hodgkin lymphoma. Hematology Am. Soc. Hematol. Educ. Program. 2009, 507-519 (2009)
22. Kato N, Fujimoto H, Yoda A et al. Regulation of Chk2 gene expression in lymphoid malignancies: involvement of epigenetic mechanisms in Hodgkin s lymphoma cell lines. Cell Death Differ. 11(Suppl. 2), S153-S161 (2004)
23. Buglio D, Georgakis GV, Hanabuchi S et al. Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines. Blood 112(4), 1424-1433 (2008)
24. Martin-Sanchez E, Sanchez-Beato M, Rodriguez ME et al. HDAC inhibitors induce cell-cycle arrest, activate the apoptotic extrinsic pathway and synergize with a novel PIM inhibitor in Hodgkin lymphomαderived cell lines. Br. J. Haematol. 152(3), 352-356 (2011)
25. Hartlapp I, Pallasch C, Weibert G, Kemkers A, Hummel M, Re D. Depsipeptide induces cell death in Hodgkin lymphomαderived cell lines. Leuk. Res. 33(7), 929-936 (2009)
26. Jona A, Khaskhely N, Buglio D et al. The histone deacetylase inhibitor entinostat (SNDX-275) targets Hodgkin lymphoma through a dual mechanism of immune modulation and apoptosis induction. Blood 116(21) (2010) (Abstract 2850)
27. DeAngelo D, Spencer A, Ottmann OG et al. Panobinostat has activity in treatment-refractory Hodgkin lymphoma. Haematologica 94(Suppl. 2) 205 (2009) (Abstract 0505).
28. Dickinson M, Ritchie D, DeAngelo DJ et al. Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin lymphoma. Br. J. Haematol. 147(1), 97-101 (2009)
29. Ellis L, Pan Y, Smyth GK et al. Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma. Clin. Cancer Res. 14(14), 4500-4510 (2008)
30. Younes A, Copeland A, Fanale MA et al. Phase I/II study of the novel combination of panobinostat (LBH589) and everolimus (RAD001) in relapsed/refractory Hodgkin and non-Hodgkin lymphoma. Blood 116(21) (2010) (Abstract 3964)
31. Duvic M, Talpur R, Ni X et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)Blood 109(1), 31-39 (2007)
32. Olsen EA, Kim YH, Kuzel TM et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J. Clin. Oncol. 25(21), 3109-3115 (2007)
33. Kirschbaum M, Popplewell L, Nademanee AP et al. A Phase 2 study of vorinostat (suberoylanilide hydroxamic acid, SAHA) in relapsed or refractory indolent non-Hodgkin s lymphoma. A California Cancer Consortium Study. Blood 112(11) (2008) (Abstract 1564)
34. Crump M, Coiffier B, Jacobsen ED et al. Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma. Ann. Oncol. 19(5), 964-969 (2008)
35. Younes A, Wedgwood A, McLaughlin P et al. Treatment of relapsed or refractory lymphoma with the oral isotype-selective histone deacetylase inhibitor MGCD0103: interim results from a Phase II study. Blood 110(11) (2007) (Abstract 2571)
36. Wardell SE, Ilkayeva OR, Wieman HL et al. Glucose metabolism as a target of histone deacetylase inhibitors. Mol. Endocrinol. 23(3), 388-401 (2009)
37. Atadja P. Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges. Cancer Lett. 280(2), 233-241 (2009)
38. Duvic M, Becker JC, Dalle S et al. Phase II trial of oral panobinostat (LBH589) in patients with refractory cutaneous T-cell lymphoma (CTCL)ASH Annual Meeting Abstracts 112(11), 1005 (2008).